Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions?
· Cervical cancer – Yes.
· Endometrial cancer – Yes.
In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments?
Q2. How many patients were treated for cervical cancer in the past 6 months with the following treatments:
· Paclitaxel in combination with Platinum and/or Bevacizumab – < 5
· Pembrolizumab in combination with Platinum and/or Bevacizumab – NIL
· Platinum standalone or in combination with Bevacizumab – NIL
· Toptecan in combination with Platinum and/or Bevacizumab – NIL
· Any other SACT – NIL
Q3. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
· Dostarlimab – < 5
· Hormone therapy (Progesterone or Letrozole) – Unknown – as prescribed in Primary Care.
· Pembrolizumab in combination with Lenvatinib – NIL
· Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) – 15
· Any other SACT – < 5
Q4. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
· Hormone therapy (Progesterone or Letrozole) – Unknown – as prescribed in Primary Care
· Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) – < 5
· Any other SACT – NIL
Q5. Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part.
The Trust does not currently have studies in this area.
Q6. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.
The Trust does not currently have studies in this area.
